

## **CFTR Antibody**



Orders: 877-616-CELL (2355)

orders@cellsignal.com

Support: 877-678-TECH (8324)

Web: info@cellsignal.com

cellsignal.com

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

## For Research Use Only. Not for Use in Diagnostic Procedures.

Applications:	Reactivity: H M R Mk	<b>Sensitivity:</b> Endogenous	<b>MW (kDa):</b> 168	<b>Source/Isotype:</b> Rabbit	UniProt ID: #P13569	Entrez-Gene Id 1080
Product Usage Information		<b>Application</b> Western Blotting			<b>Dilution</b> 1:1000	
Storage		Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 $\mu$ g/ml BSA and 50% glycerol. Store at – 20°C. Do not aliquot the antibody.				
Specificity/Sensitivity		CFTR Antibody detects endogenous levels of total CFTR protein.				
Source / Purification		Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to amino acids near the amino terminus of human CFTR. Antibodies are purified by protein A and peptide affinity chromatography.				
Background		CFTR (ABC35, ABCC7, CBAVD, CF, dj760C5.1, MRP7, TNR-CFTR) is a member of the ATP-binding cassette (ABC) transporter superfamily. Mutations in ABC genes have been linked to many diseases. CFTR is a plasma membrane cyclic AMP activated chloride channel that is expressed in the epithelial cells of the lung and several other organs (1,2). It mediates the secretion of Cl- and also regulates several channels including the epithelial sodium channel (ENaC), K+ channels, ATP release mechanisms, anion exchangers, sodium bicarbonate transporters and aquaporin water channels (3,4,5,6,7,8 9,10). Mutations in the CFTR gene cause cystic fibrosis, a disease that is characterized by exocrine pancreatic insufficiency, increase in sweat gland NaCl, male infertility and airway disease (1,2,11). Intracellular trafficking regulates the number of CFTR molecules at the cell surface, which in part regulates Cl-secretion. Deletion of phenylalanine 508 (deltaF508) is the most common mutation in CF patients. This mutation results in retention in the ER, where ER quality control mechanisms target the deltaF508 mutant to the proteosome for degradation (12-14). Therefore, disruption of CFTR trafficking leads to disregulation of CI- secretion at the plasma membrane of epithelial cells.				
Background References		2. Bertrand, C.A. and I 3. Ko, S.B. et al. (2004) 4. Ji, H.L. et al. (2000) 5. Jiang, Q. et al. (2000 6. Stutts, M.J. et al. (19 7. Cheung, K.H. et al. (8. Shumaker, H. et al. (9. Schwiebert, E.M. et 10. Yoo, D. et al. (2004) 11. Cohn, J.A. et al. (2012) 12. Gibson, R.L. et al. (13. Boucher, R.C. (2004)	et al. (1999) <i>Am. J. Physiol.</i> 276, L659-L668. and Frizzell, R.A. (2003) <i>Am. J. Physiol. Cell Physiol.</i> 285, C1-C18. 2004) <i>Nat. Cell Biol.</i> 6, 343-350. 000) <i>J. Biol. Chem.</i> 275, 27947-27956. (2000) <i>J. Biol. Chem.</i> 275, 13266-13274. al. (1997) <i>J. Biol. Chem.</i> 272, 14037-14040. et al. (2003) <i>Biol. Reprod.</i> 68, 1505-15010. et al. (1999) <i>Am. J. Physiol.</i> 276, C16-C25. M. et al. (1999) <i>Physiol. Rev.</i> 79, S145-S166. (2004) <i>J. Biol. Chem.</i> 279, 6863-6873. al. (2005) <i>Hum. Mutat.</i> 26, 303-307. et al. (2003) <i>Am. J. Respir. Crit. Care Med.</i> 168, 918-951. (2004) <i>Eur. Respir. J.</i> 23, 146-158. 2005) <i>Annu. Rev. Physiol.</i> 67, 701-718.			

**Species Reactivity** 

**Applications Key** 

Species reactivity is determined by testing in at least one approved application (e.g., western blot).

**Western Blot Buffer** 

IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.

W: Western Blotting

**Cross-Reactivity Key** 

H: Human M: Mouse R: Rat Mk: Monkey

**Trademarks and Patents** 

Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.

All other trademarks are the property of their respective owners. Visit cellsignal.com/trademarks for more information.

## **Limited Uses**

Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.

Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party. whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.